中文名:Cilomilast
英文名:Cilomilast
英文別名:SB-207499;4-cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylic acid
純度:10mM in DMSO
貨號:C408476
包裝:1ml
Cas號:153259-65-5
存儲溫度:-80℃儲存
產品介紹:
Information
Cilomilast (SB-207499) is a potentPDE4inhibitor withIC50of about 110 nM, has anti-inflammatory activity and low central nervous system activity. Phase 3.
In?vitro
Cilomilast produces a concentration-dependent increase in cAMP content in U937 cells. Cilomilast produces a concentration-dependent increase in cAMP content in U937 cells. In isolated human monocytes, Cilomilast and (R)-rolipram are equipotent at suppressing LPS-induced TNF-α formation with -log (IC50) of 7.0 and 7.2, respectively. Both Cilomilast and (R)-rolipram produces a modest prevention of fMLP-induced degranulation of human neutrophils. Cilomilast and (R)-rolipram are equipotent at suppressing neutrophil activation with -log (IC50) of 7.1 and 6.4, respectively. Cilomilast significantly decreases the expression of TNF-α in the cornea and IL-1α, IL-1β, and TNF-α in the conjunctivaas compared to vehicle control. Cilomilast treatment markedly decreases the presence of CD11b+ antigen-presenting cells in the central and peripheral cornea, and leads to decreased conjunctival expression of cytokines IL-6, IL-23, and IL-17. Moreover, Cilomilast decreases the expression of IL-17 and IL-23 in the draining lymph nodes. Cilomilast reduces TLR4 expression, IL-8 release and neutrophil chemotactic activity as well as it increased IP-10 release and lymphocyte chemotactic activity.
In?vivo
Cilomilast inhibits human TNFα production with oral ED50 of 4.9 mg/kg. In contrast to their equipotent activity against TNFα production, Cilomilast (ED50 = 2.3 mg/kg, p.o.) is 10-fold less potent than R-rolipram (ED50 = 0.23 mg/kg, p.o.) in reversing reserpine-induced hypothermia, a model of antidepressant activity. In time course studies, Cilomilast (30 mg/kg, p.o.) suppresses TNFα production for at least 10 hour. The ability of Cilomilast to modulate interleukin-4 productionin vivo is assessed in a chronic oxazolone-induced contact sensitivity model in Balb/c mice. Topical administration of Cilomilast (1000 μg) inhibits intralesional concentrations of interleukin-4. Orally administered cilomilast dose-dependently inhibits production of interleukin-4, TNF-α, and cysteinyl leukotrienes, as well as leukocyte infiltration in bronchoalveolar lavage fluid from the airways of ovalbumin-sensitized Brown Norway rats .
Cell?Data
cell?lines:
Concentrations:0.1-10 μM
Incubation?Time:5 min
Powder?Purity:≥95%
查看阿拉丁官網此產品相關對應頁面:https://www.aladdin-e.com/zh_cn/C408476.html
關鍵字: SB-207499;4-cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylic acid
上海阿拉丁生化科技股份有限公司是A股上市公司((股票代碼:688179),專注于科研試劑的研發(fā)、生產和銷售,已陸續(xù)建立多個工廠和研發(fā)中心。作為領軍企業(yè),阿拉丁始終堅持質量第一,連續(xù)13年被評為“最受歡迎試劑品牌”。
阿拉丁目前常備庫存試劑產品品種超過7萬種,SKU總數超過46萬,產品線涵蓋了化學試劑、生化試劑、藥靶配體、蛋白質和抗體等多個領域,是國內少數化學試劑到生物試劑全面發(fā)展的國產試劑品牌,產品同步發(fā)布在我們國內外電商平臺。